---
title: "Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295430908.md"
description: "H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics with a $1.20 price target, citing clinical momentum for lead drug APR-1051. Key drivers include increased active sites and accelerated enrollment in the Phase 1 ACESOT-1051 study, alongside strategic expansion into combination therapies for HPV-positive head and neck cancer and KRAS/TP53-mutant colorectal cancer. These developments validate the drug's tolerability profile and support a positive outlook."
datetime: "2026-08-10T16:25:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295430908.md)
  - [en](https://longbridge.com/en/news/295430908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295430908.md)
generator: "portal-rs"
---

# Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Aprea Therapeutics, retaining the price target of $1.20.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Joseph Pantginis has given his Buy rating due to a combination of factors tied to the progress of Aprea’s lead WEE1 inhibitor program, APR-1051. He views the significant increase in active clinical sites for the Phase 1 ACESOT-1051 study and the guided acceleration in patient enrollment as a meaningful shift that should enable more robust and timely clinical data generation.

Pantginis also highlights the strategic expansion into combination settings in HPV-positive head and neck cancer and KRAS/TP53-mutant colorectal cancer as an important validation of APR-1051’s potential differentiation in tolerability. With biomarker-driven cohorts advancing in parallel and a clear timeline toward dose optimization by 2027, he believes the program’s evolving profile supports maintaining a positive stance on the stock, reflected in his unchanged $1.20 price target.

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)

## Related News & Research

- [Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | APRE Stock News](https://longbridge.com/en/news/297324671.md)
- [Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trial](https://longbridge.com/en/news/294362918.md)
- [Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz](https://longbridge.com/en/news/297419518.md)
- [Abbisko unit Abbisko Therapeutics doses first patient in Phase I trial of pan-KRAS inhibitor ABSK211](https://longbridge.com/en/news/297476007.md)
- [Abbisko Therapeutics Begins First-in-Human Trial of Novel Pan-KRAS Cancer Drug ABSK211](https://longbridge.com/en/news/297452401.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**